文献速递MDS 与骨髓增殖性肿瘤

CAMK2G被确定为骨髓纤维化的新型治疗靶点

CAMK2G is identified as a novel therapeutic target for myelofibrosis.
PubMed 文献 · Blood Adv · 2022-01-01

研究利用携带JAK2 V617F、CALR 1型或CALR 2型突变的骨髓纤维化患者来源iPSCs进行化学筛选,鉴定出CAMK2为有前景的治疗靶点。在MPL W515L诱导的MF模型细胞和小鼠中,CAMK2抑制对JAK2抑制剂敏感和耐药细胞均有效,CAMK2G抑制剂小檗胺显著延长生存并减轻脾大和白细胞增多。

要点

  • CAMK2抑制对JAK2抑制剂敏感及耐药的MF细胞均有效。
  • CAMK2G杂合敲除降低表达MPL W515L的原代骨髓细胞集落形成能力。
  • 小檗胺抑制CAMK2G可延长MPL W515L诱导MF小鼠生存并减轻疾病表型。

核心结论

  • CAMK2G在骨髓纤维化中起重要作用,抑制CAMK2G可能成为克服JAK1/2抑制剂耐药的新型治疗策略。

研究设计与样本

  • 建立携带JAK2 V617F、CALR 1型或CALR 2型突变的骨髓纤维化患者来源iPSCs并进行化学筛选。
  • 使用MPL W515L诱导的MF模型细胞和小鼠评估CAMK2抑制的治疗潜力。

主要发现

  • MF-iPSCs可忠实再现疾病的药物敏感性。
  • CAMK2抑制对JAK2抑制剂敏感和耐药的细胞均有效。
  • CAMK2 γ亚型在MPL W515L诱导的MF模型细胞中重要。
  • CAMK2G杂合敲除降低表达MPL W515L的原代骨髓细胞集落形成能力。
  • 小檗胺抑制CAMK2G显著延长MPL W515L诱导MF小鼠生存并减轻脾大、白细胞增多等疾病表型。

临床怎么用

  • CAMK2G抑制可作为克服JAK1/2抑制剂耐药的新策略,小檗胺为候选CAMK2G抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although JAK1/2 inhibition is effective in alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here, we established induced pluripotent stem cells (iPSCs) derived from MF patient samples (MF-iPSCs) harboring JAK2 V617F, CALR type 1, or CALR type 2 mutations. We demonstrated that these cells faithfully recapitulate the drug sensitivity of the disease. These cells were used for chemical screening, and calcium/calmodulin-dependent protein kinase 2 (CAMK2) was identified as a promising therapeutic target. MF model cells and mice induced by MPL W515L, another type of mutation recurrently detected in MF patients, were used to elucidate the therapeutic potential of CAMK2 inhibition. CAMK2 inhibition was effective against JAK2 inhibitor-sensitive and JAK2 inhibitor-resistant cells. Further research revealed CAMK2 γ subtype was important in MF model cells induced by MPL W515L. We showed that CAMK2G hetero knockout in the primary bone marrow cells expressing MPL W515L decreased colony-forming capacity. CAMK2G inhibition with berbamine, a CAMK2G inhibitor, significantly prolonged survival and reduced disease phenotypes, such as splenomegaly and leukocytosis in a MF mouse model induced by MPL W515L. We investigated the molecular mechanisms underlying the therapeutic effect of CAMK2G inhibition and found that CAMK2G is activated by MPL signaling in MF model cells and is an effector in the MPL-JAK2 signaling pathway in these cells. These results indicate CAMK2G plays an important role in MF, and CAMK2G inhibition may be a novel therapeutic strategy that overcomes resistance to JAK1/2 inhibition.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Miyauchi M, Sasaki K, Kagoya Y, et al. CAMK2G is identified as a novel therapeutic target for myelofibrosis. Blood Adv. 2022. PMID: 34521112. doi:10.1182/bloodadvances.2020003303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。